- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04831606
Blue Light Photobiomodulation Therapy on Neuroischemic Patients (HERMES)
A Single-center Prospective Randomized Controlled Study on the Efficacy of Blue Light in the Therapy of Neuro-ischemic Foot Lesions in Patients With Type I or II Diabetes in a Combined Hospital /Territory Treatment Regimen.
This is a pilot case/control clinical study on a group of outpatients with diabetic foot lesions aiming to verify the efficacy and safety of the Blue light photobiomodulation therapy with EmoLED medical device, in addition to standard therapy compared to the standard therapy alone, evaluating the percentage of healed lesions (which have reached complete and lasting re-epithelialization), the evaluation of the healing time and reduction of the ulcerated area during the time of observation, the perception of pain and the quality of life of the enrolled patients.
The aim of this study is therefore to determine any differences in outcome between the two groups considered and, in particular, if the therapy of the group being treated is more effective than the standard therapy in terms of percentage of healed lesions, healing time, and reduction of the ulcerated area, pain perception, and quality of life, and is at least as safe in terms of occurrence of adverse events.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be conducted according to the standards of Good Clinical Practice and in compliance with the principles set out in the Declaration of Helsinki, with the UNI_ISO_14155_2011 standard, and with all relevant local laws and regulations applicable to clinical trials that use patients as the research object. This clinical investigation in the various centers involved cannot begin before having received the favorable written approval of the Ethics Committee of the coordinating center and the respective Ethics Committees. The medical assistance provided to the subject is the responsibility of adequately qualified doctors, as all the centers involved in this study are centers specialized in the treatment of the pathology object of the clinical trial (Diabetology units or Diabetic Foot clinics).
During this trial, the patients' right to physical and mental integrity, the right to privacy, and the protection of data concerning them will be respected following Directive 95/46/EC.
This clinical investigation has been designed in such a way as to cause as little pain, discomfort, fear, and other foreseeable risks for the subject as possible and the degree of discomfort related to the trial itself or the treatment with the medical device in question is almost nil, considered the clinical evaluation report of the device and the safety data obtained from post-marketing surveillance.
The degree of discomfort/pain of the enrolled patients is however subject to continuous verification during the clinical trial, through a special questionnaire on the detection of discomfort connected to participation in the study in question. The risk/benefit ratio will be constantly checked throughout the trial, taking into account any adverse events / device-related accidents or non-serious side effects reported by the main investigators, and the preliminary assessment of the benefits found on patients who have completed the study process.
The principal investigator of each center is responsible for adequate conduct of the study of his own center and the coordination of the personnel involved. Must be responsible for all medical decisions relating to the study and ensure that adequate medical assistance is provided to the subject in case of adverse events. The investigator should conduct the study following the protocol agreed with the sponsor and the authorities.
To verify that the rights, safety, and well-being of enrolled patients are protected, that the data communicated are reliable and solid, and that the clinical investigation is conducted in compliance with the prescriptions of current legislation, the sponsor guarantees adequate monitoring of the conduct of this clinical investigation. The monitoring of the clinical investigation is entrusted to the sponsor's staff adequately trained. To ensure compliance with ICH/GCP guidelines and current legislation, such personnel will be responsible for ensuring that the Study is conducted in full compliance with the Standard Operating Procedures, the Protocol, and other written instructions.
The main responsibilities of the personnel carrying out the monitoring are to ensure adherence to the Protocol, to ensure that data is recorded and reported accurately and completely, and to verify that informed consent has been obtained and recorded for all subjects before they participate in the study. Researchers will be contacted at regular intervals throughout the study period. To check and verify the various documents (Data Collection Cards or CRFs and other relevant documents containing the original data) relating to the Study to verify compliance with the Protocol and to ensure the completeness, consistency, and accuracy of the recorded data.
Monitoring staff will conduct a center opening visit (SIV), a minimum of three visits during the study (MOV) to be scheduled approximately one after 1 or 2 months after SIV based on the number of patients enrolled, one at two-thirds of the enrollment and another after the observations on the last patient. Finally, once all the open issues have been resolved (open queries, clarifications, etc.), we will proceed with the center closing visit (COV). Should additional monitoring visits be necessary, the staff will schedule them with the principal investigator.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Duccio Rossi, Biologist
- Phone Number: +390550751960
- Email: d.rossi@emoled.com
Study Contact Backup
- Name: Magali Maffucci, Biologist
- Phone Number: +390550751960
- Email: m.maffucci@emoled.com
Study Locations
-
-
-
Arezzo, Italy, 52100
- Recruiting
- San Donato Hospital
-
Contact:
- Alessia Scatena, Doctor
- Phone Number: +393283281501
- Email: alessia.scatena@uslsudest.toscana.it
-
Sub-Investigator:
- Sara Sandroni, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients suffering from neuro-ischemic diabetic foot ulcer grade IC or IIC according to the University of Texas Wound Classification; If the patient has two or more lesions, which may fall within the inclusion criteria, the most serious lesion (index lesion) will be selected and followed for the entire duration of the study.
- Patients who, following hospital discharge or after the first outpatient assessments, are followed by Home Care and are always monitored at the same referral center;
- Patients with type I or II diabetes, with blood glucose ≤ 10%;
- Patients willing to constantly wear the offload braces prescribed by the reference center;
- Patients with ulcer localized on the finger, lateral, plantar, or dorsal part of the foot with an extension greater than 1 sqcm;
- Patients with confirmed neuropathy with Monofilament (Semmes-Weinstein 5.07 / 10g);
- Patients with ABPI between 0.7 - 0.9, ankle PA> 70mmHg, TcPO2 between 36 - 50 mmHg;
- Patients with lesions lasting between 1 and 24 months;
- Patients who understand the purpose of the Clinical Study and provide their informed consent in writing.
Exclusion Criteria:
- Patients who have participated in a clinical study with a drug or medical device for less than a month;
- Patients who are unable to understand the aims and objectives of the study;
- Patients who are bedridden or unable to walk or Patients with neoplasms;
- Patients with pressure ulcers;
- Patients who have infectious signs according to IDSA criteria;
- Patients who underwent revascularization in the previous two months;
- Patients who have presented an acute ischemic event within the previous 3 months;
- Patients with heel injuries;
- Patients with nephropathy undergoing dialysis;
- Patients with osteomyelitis;
- Patients with Charcot's neuro-arthropathy:
- Patient on high dose corticosteroid therapy (≥ 40 mg/day);
- Patients with a history of self-harm who can voluntarily alter the course of healing;
- Patients with psychiatric disorders;
- Women who are pregnant or breastfeeding;
- Patients with pathologies or under treatment with drugs that induce photosensitization of the skin;
- Patients with a life expectancy of less than one year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Arm
Patients will receive a biweekly standard treatment at home according to the International Working Group on Diabetic Foot consisting of: Debridement of the lesion, unloading with a brace up to the calf, non-removable (except for contraindications), dressing of the wound with advanced dressings in use at the specialized center and in the home care network.
|
Cleaning of the wound area
Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
Protect the wound with Advanced dressing
|
Experimental: EmoLED Arm
Patients on top of the standard treatment of the control arm will receive EmoLED blue light irradiation for two minutes at each biweekly medication.
|
Cleaning of the wound area
Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
Protect the wound with Advanced dressing
2 minutes irradiation of blue light performed with EmoLED device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of healed lesions on the total lesions treated for each arm
Time Frame: 24 weeks (20 weeks treatment plus 4 weeks post treatment observation)
|
Percentage of lesions showing a lasting and complete re-epithelialization in each group after twenty-four weeks. Healing must be confirmed by the Principal Investigator or his staff during an outpatient visit at the reference center participating in the study |
24 weeks (20 weeks treatment plus 4 weeks post treatment observation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Healing time
Time Frame: 24 weeks
|
Number of days needed to reach a lasting and complete re-epithelialization within the observation period
|
24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of the lesion surface in both arms, measured in absolute terms (square centimeters) and as % of the initial size.
Time Frame: once every 4 weeks for 20 weeks plus the last control visit at 24 weeks if needed
|
At each outpatient control visit, a photograph image will be acquired with the device in the use of the structure (WoundViewer from Omnidermal Biomedics Srl).
The device takes pictures and calculates automatically the area of the wounds through a validated algorithm.
|
once every 4 weeks for 20 weeks plus the last control visit at 24 weeks if needed
|
Quality of life level (QoL), measured with specific questionnaires (EuroQoL-5D)
Time Frame: 16 weeks (last outpatient visit)
|
At the first and last visit in the outpatient center information on the patient's quality of life will be collected using standard models such as the EQ-5D and the Wound-QoL both available and validate in the Italian language.
|
16 weeks (last outpatient visit)
|
Pain perception measured according to the VAS scale
Time Frame: 20 weeks
|
At each visit the patient pain perception will be measured using the standard VAS scale method
|
20 weeks
|
Comparative Evaluation of costs associated with the therapy.
Time Frame: 16 weeks
|
Both sanitary costs and patients' costs (including caregiver if present) in connection with the therapy will be recorded. Through a questionnaire to be filled at the last visit by the patient, the caregiver, the home nurse, and the outpatient center all direct, indirect, medical personnel, and societal costs will be recorded. the home nurses and outpatient center will fill a questionnaire regarding direct and indirect costs connected with the therapy for both arms. |
16 weeks
|
Patient's therapy acceptance
Time Frame: 24 weeks
|
at the control visit a questionnaire to evaluate the therapy's acceptance will be given to patients of both arms.
|
24 weeks
|
Appreciation, complexity and usefulness of the EmoLED therapy by the operator
Time Frame: 24 weeks
|
a specific questionnaire will be administered to the personnel to evaluate appreciation, complexity and usefulness of the EmoLED therapy.
|
24 weeks
|
Number of Treatment-Emergent Adverse Events
Time Frame: 24 weeks
|
All incidents according to the definition of the EU regulation 2017/745 on Medical Devices will be properly reported their gravity and relation with the therapy evaluated. It will be counted the number and gravity of occurred adverse events on both arms |
24 weeks
|
Evaluation of cost-effectiveness of using EmoLED for the treatment of ulcers
Time Frame: 24 weeks
|
Evaluation of cost-effectiveness using EmoLED in the treatment of ulcers through economic-organizational impact survey.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Alberto Piaggesi, Doctor, Pisa University Hospital
- Principal Investigator: Alessia Scatena, Doctor, San Donato Hospital
Publications and helpful links
General Publications
- Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen. 1996 Oct;4(4):411-20. doi: 10.1046/j.1524-475X.1996.40404.x.
- Greenhalgh DG. Management of Burns. N Engl J Med. 2019 Jun 13;380(24):2349-2359. doi: 10.1056/NEJMra1807442. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EmoLED_DF_001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on debridement
-
Smith & Nephew, Inc.TerminatedTorn MeniscusUnited States
-
Medaxis, LLCNAMSARecruitingDiabetic Foot Ulcer | Venous Leg Ulcer | Surgical Wound Dehiscence | Traumatic WoundsUnited States
-
Hospital for Special Surgery, New YorkTerminated
-
North Florida Foundation for Research and EducationNorth Florida/South Georgia Veterans Health System; BiomondeCompletedBacterial Infection | Lower Extremity or Diabetic Foot UlcersUnited States
-
National Taiwan University HospitalUnknown
-
University of MichiganMorita J USACompleted
-
Scil Technology GmbHFGK Clinical Research GmbHUnknownPeriodontal Bone Loss | Alveolar Bone LossHungary
-
Ain Shams UniversityNot yet recruitingPeriodontal Diseases
-
St. Paul's Hospital, CanadaUnknown
-
Southwest Regional Wound Care CenterWithdrawn